RU2021131224A - Антитела, нацеленные на о-антиген на основе галактана из k. pneumoniae - Google Patents

Антитела, нацеленные на о-антиген на основе галактана из k. pneumoniae Download PDF

Info

Publication number
RU2021131224A
RU2021131224A RU2021131224A RU2021131224A RU2021131224A RU 2021131224 A RU2021131224 A RU 2021131224A RU 2021131224 A RU2021131224 A RU 2021131224A RU 2021131224 A RU2021131224 A RU 2021131224A RU 2021131224 A RU2021131224 A RU 2021131224A
Authority
RU
Russia
Prior art keywords
antibody
sequence
seq
galactan
klebsiella pneumoniae
Prior art date
Application number
RU2021131224A
Other languages
English (en)
Russian (ru)
Inventor
Валерия ШИЯРТО
Габор Наги
Луис ГУАЧАЛЛА
Зера ВИСРАМ
Эстер Наги
Йоланта Катаржина ЛУКАСЕВИЧ
Original Assignee
Х4 Фармасьютикалз (Австрия) ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х4 Фармасьютикалз (Австрия) ГмбХ filed Critical Х4 Фармасьютикалз (Австрия) ГмбХ
Publication of RU2021131224A publication Critical patent/RU2021131224A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26—Klebsiella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2021131224A 2015-02-17 2015-11-03 Антитела, нацеленные на о-антиген на основе галактана из k. pneumoniae RU2021131224A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15155448.2 2015-02-17
EP15155448 2015-02-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2017132168A Division RU2759950C2 (ru) 2015-02-17 2015-11-03 Антитела, нацеленные на о-антиген на основе галактана из к.pneumoniae

Publications (1)

Publication Number Publication Date
RU2021131224A true RU2021131224A (ru) 2021-11-03

Family

ID=52469764

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2021131224A RU2021131224A (ru) 2015-02-17 2015-11-03 Антитела, нацеленные на о-антиген на основе галактана из k. pneumoniae
RU2017132168A RU2759950C2 (ru) 2015-02-17 2015-11-03 Антитела, нацеленные на о-антиген на основе галактана из к.pneumoniae

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017132168A RU2759950C2 (ru) 2015-02-17 2015-11-03 Антитела, нацеленные на о-антиген на основе галактана из к.pneumoniae

Country Status (12)

Country Link
US (2) US11466074B2 (https=)
EP (1) EP3259287A1 (https=)
JP (2) JP6987638B2 (https=)
KR (1) KR20170122726A (https=)
CN (1) CN107371365B (https=)
AU (1) AU2015383632B2 (https=)
BR (1) BR112017017553A2 (https=)
CA (1) CA2973134A1 (https=)
IL (1) IL253920B2 (https=)
MX (1) MX2017009955A (https=)
RU (2) RU2021131224A (https=)
WO (1) WO2016131503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017017553A2 (pt) * 2015-02-17 2018-05-08 Arsanis Biosciences Gmbh ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
SG11201903063UA (en) * 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN120775040A (zh) * 2021-08-25 2025-10-14 北京三诺佳邑生物技术有限责任公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
CN118620072A (zh) * 2023-12-27 2024-09-10 上海博钒生物科技有限公司 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
BR112017017553A2 (pt) * 2015-02-17 2018-05-08 Arsanis Biosciences Gmbh ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?

Also Published As

Publication number Publication date
KR20170122726A (ko) 2017-11-06
JP2018508208A (ja) 2018-03-29
BR112017017553A2 (pt) 2018-05-08
US20180066041A1 (en) 2018-03-08
CN107371365A (zh) 2017-11-21
CA2973134A1 (en) 2016-08-25
MX2017009955A (es) 2017-10-19
AU2015383632A1 (en) 2017-07-27
CN107371365B (zh) 2022-01-11
IL253920B (en) 2022-10-01
IL253920B2 (en) 2023-02-01
US20230220055A1 (en) 2023-07-13
EP3259287A1 (en) 2017-12-27
JP6987638B2 (ja) 2022-01-05
AU2015383632B2 (en) 2021-10-21
RU2759950C2 (ru) 2021-11-19
WO2016131503A1 (en) 2016-08-25
IL253920A0 (en) 2017-10-31
US11466074B2 (en) 2022-10-11
RU2017132168A3 (https=) 2019-06-11
RU2017132168A (ru) 2019-03-18
JP2022058341A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
RU2021131224A (ru) Антитела, нацеленные на о-антиген на основе галактана из k. pneumoniae
Neto et al. Antibody responses of swine following infection with Mycoplasma hyopneumoniae, M. hyorhinis, M. hyosynoviae and M. flocculare
JP2012515551A5 (https=)
RU2018119273A (ru) Антитела, нацеленные на основанный на маннане о-антиген к. pneumoniae
CN104862283B (zh) 一对高特异性高亲和力结合人肌红蛋白的单克隆抗体及其应用
JP2013505938A5 (https=)
JP2009536818A5 (https=)
Sarkissian et al. UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens
CN103635591A (zh) 由免疫复合物直接对微生物进行测序的测定法与方法
RU2018117651A (ru) Бактерицидное моноклональное антитело, нацеленное на klebsiella pneumoniae
US8703432B2 (en) Recombinant Treponema spp. proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
CN117700537A (zh) 一种与非洲马瘟病毒vp7蛋白具有良好亲和反应能力的单克隆抗体及用途
CN102876635B (zh) 抗副猪嗜血杆菌外膜蛋白omp5的单克隆抗体、杂交瘤细胞株及应用
CN110437326B (zh) 大疱性类天疱疮BP230 IgE抗体的抗原表位多肽及其用途
RU2549698C2 (ru) Химерный белок боррелии, нуклеиновая кислота, кодирующая такой белок, экспрессирующая кассета, вектор, способ и набор для диагностики лайм-боррелиоза, вакцина для профилактики боррелиоза
WO2017125007A1 (zh) 用于诊断活动性结核的方法和试剂盒
CN102775486B (zh) 监测肾损伤的新型试剂和试剂盒
Chen et al. Screening of antigenic epitopes related to the adhesion of the avian Escherichia coli Type 1 Fimbrial Agglutinin Domain
CN114736295B (zh) 一种辣根过氧化物酶标记抗体及其制备方法
CN113648409A (zh) L-鼠李糖抗体在制备预防和/或治疗耐药细菌感染的药物中的应用
CN114989297B (zh) 包含辣根过氧化物酶标记的抗体的试剂盒
Bannantine et al. Production and characterization of monoclonal antibodies against a major membrane protein of Mycobacterium avium subsp. paratuberculosis
RU2546246C2 (ru) Химерный белок, используемый для диагностики лайм-боррелиоза.
Bannantine et al. Monoclonal antibodies bind a SNP-sensitive epitope that is present uniquely in Mycobacterium avium subspecies paratuberculosis
CN110862969B (zh) 分泌抗cfp-10抗体的杂交瘤细胞株、其抗体及其应用